eligibility_summary
Inclusion: Adults (≥18) who initiated a biologic for SA between Oct 1, 2021 and Sep 30, 2022 and received at least one dose. Exclusion: Participation in any interventional clinical trial during the study period or within ±12 months of the index date.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06261567 is a completed retrospective chart review of severe asthma patients in the UK NHS treated with biologic monoclonal antibodies to assess clinical remission. Interventions: omalizumab (anti-IgE mAb, binds free IgE, downregulates FcεRI on mast cells/basophils, attenuates allergic cascade), mepolizumab and reslizumab (anti–IL-5 mAbs, neutralize IL-5, reducing eosinophil maturation/survival), benralizumab (anti–IL-5Rα mAb, induces ADCC to deplete eosinophils and basophils), dupilumab (anti–IL-4Rα mAb, blocks IL‑4/IL‑13 signaling, reducing type 2 inflammation and IgE class switching). Targeted cells/pathways: eosinophils, basophils, mast cells, B-cell IgE pathway, Th2/type‑2 cytokines (IL‑4/IL‑13), IL‑5/IL‑5R axis, FcεRI-mediated allergic signaling.